236 completed, 113 recruiting, 84 terminated, 83 unknown. 648 Phase 2, 207 Phase 1, 32 Phase 3.
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-08-26 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
| Menin-Inhibitor Targeted Maintenance in AML Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications | Phase 2 | Not yet recruiting | Center for International Blood and Marrow Transplant Research | 146 | 2026-12-01 | 2026-06-22 |
| Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia GA-directed treatment regimens - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | University of Rochester | 120 | 2026-12-01 | 2026-07-29 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML fludarabine and treosulfan - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 77 | 2026-10-10 | 2026-05-20 |
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 126 | 2026-09-25 | 2026-10-29 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) Levofloxacin, Usual Care - Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) | Phase 2 | Not yet recruiting | University of Manitoba | 75 | 2026-09-01 | 2026-06-29 |
| Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. Ivosidenib + oral azacitidine - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 60 | 2026-09-01 | 2026-03-11 |
| Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia gilteritinib-azacitidine-venetoclax - Acute Myeloid Leukemia, AML With FLT3 Mutation | Phase 2 | Not yet recruiting | Florian Kuchenbauer | 20 | 2026-09-01 | 2026-10-02 |
Showing 20 of 648. Sign in to see all of them.
Leukemia, Myeloid, Acute (648) · Myelodysplastic Syndromes (197) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (109) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (67) · Leukemia (58) · Leukemia, Myelomonocytic, Chronic (49) · Myeloproliferative Disorders (38) · Leukemia, Biphenotypic, Acute (36) · Lymphoma, Non-Hodgkin (34) · Hodgkin Disease (30) · Recurrence (30) · Leukemia, Lymphocytic, Chronic, B-Cell (29) · Multiple Myeloma (26) · Anemia, Refractory, with Excess of Blasts (22) · Hematologic Neoplasms (20)
Hemic and Lymphatic Diseases (648) · Neoplasms by Histologic Type (647) · Leukemia, Myeloid (643) · Hematologic Diseases (636) · Neoplasms (632) · Leukemia (590) · Bone Marrow Diseases (231) · Pathological Conditions, Signs and Symptoms (165) · Pathologic Processes (163) · Disease Attributes (153) · Immunoproliferative Disorders (137) · Immune System Diseases (136) · Lymphoproliferative Disorders (136) · Lymphatic Diseases (134) · Leukemia, Lymphoid (124)
Cytarabine (135) · Azacitidine (114) · venetoclax (96) · fludarabine (56) · Cyclophosphamide (51) · Decitabine (50) · Daunorubicin (42) · Idarubicin (41) · Whole-Body Irradiation (37) · fludarabine phosphate (33) · Mycophenolic Acid (32) · Busulfan (31) · Specimen Handling (30) · Granulocyte Colony-Stimulating Factor (29) · Tacrolimus (27)
M.D. Anderson Cancer Center (46) · National Cancer Institute (NCI) (28) · Fred Hutchinson Cancer Center (21) · The First Affiliated Hospital of Soochow University (20) · Masonic Cancer Center, University of Minnesota (17) · Novartis Pharmaceuticals (10) · Washington University School of Medicine (8) · City of Hope Medical Center (7) · Nanfang Hospital, Southern Medical University (7) · Technische Universität Dresden (7) · French Innovative Leukemia Organisation (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (6) · Institut Paoli-Calmettes (6) · Institute of Hematology & Blood Diseases Hospital, China (6) · Memorial Sloan Kettering Cancer Center (6)
United States (345) · China (94) · Germany (65) · France (61) · Italy (43) · Canada (42) · Spain (37) · United Kingdom (27) · South Korea (23) · Australia (20) · Israel (14) · Netherlands (12) · Poland (11) · Russia (11) · Sweden (11)
Farhad Ravandi-Kashani, MD (4) · Qifa Liu (4) · Xiaowen Tang, Ph.D (4) · Anna Halpern (3) · Brenda Sandmaier (3) · Courtney DiNardo, MD (3) · Hagop M Kantarjian, MD (3) · Junmin Li (3) · Musa Yilmaz (3) · Tapan M Kadia (3) · Amanda Cashen, M.D. (2)
PMID 33394722, PMID 36184192, PMID 28054442, PMID 29702001, PMID 30062662, PMID 31171508, PMID 33741715, PMID 34267079, PMID 40073835, PMID 40513054, PMID 41621809, PMID 42013378, PMID 11015443, PMID 11313690, PMID 12242449, PMID 12721664, PMID 14603333, PMID 15297412, PMID 15800326, PMID 16313258, PMID 16564913, PMID 17038533, PMID 17213292, PMID 17255288, PMID 17273561, PMID 17360651, PMID 17363736, PMID 18294387, PMID 18565853, PMID 18596741, PMID 18756622, PMID 18997171, PMID 19023118, PMID 19059939, PMID 19151774, PMID 19188168, PMID 19284416, PMID 19417016, PMID 19420358, PMID 19423728, PMID 19509382, PMID 19602710, PMID 19706886, PMID 19724059, PMID 19952961, PMID 20026805, PMID 20371346, PMID 20564154, PMID 20570856, PMID 20733120
P30CA015704 (11), U10CA180821 (7), 2018 (6), P01CA078902 (5), U10CA031946 (5), U10CA180888 (5), UM1CA186689 (5), P30CA033572 (4), U10CA180820 (4), 2005 (3), 2008 (3), 2023 (3), 2025 (3), P30CA016672 (3), P50CA171963 (3)